Advertisement

Treatment

  • Marta Díaz-MenéndezEmail author
  • Clara Crespillo-Andújar
Chapter
Part of the SpringerBriefs in Immunology book series (BRIEFSIMMUN)

Abstract

ZIKV is a self-limited disease whose management consists of symptomatic supportive treatment with minor analgesic. Nonsteroidal anti-inflammatory drugs and aspirin should be avoided until Dengue infection could be ruled out. Multiple effective compounds have been described as having anti-ZIKV activity, but further research is needed to assess the efficacy in real infected patients. Currently, there is not an available vaccine yet. Candidate vaccines against ZIKV infection have shown promising data in efficacy in mice and non-human primates. The development of a ZIKV vaccine for humans is likely to be readily achievable within the next few years and several studies are now in Phase I.

Keywords

Dengue Infection Central Nervous System Cell ZIKV Infection Reye Syndrome Flavivirus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Schrör K (2007) Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs 9(3):195–204CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Organization (2016) Psychosocial support for pregnant women and for families with microcephaly and other neurological complications in the context of Zika virus. http://appswhoint/iris/bitstream/10665/204492/1/WHO_ZIKV_MOC_166_engpdf?ua=. Accessed 5 Jan 2017Google Scholar
  3. 3.
    Bullard-Feibelman KM, Govero J, Zhu Z, Salazar V, Veselinovic M, Diamond MS et al (2017) The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res 137:134–140CrossRefPubMedGoogle Scholar
  4. 4.
    Mumtaz N, van Kampen JJA, Reusken CBEM, Boucher CAB, Koopmans MPG (2016) Zika virus: where is the treatment? Curr Treat Options Infect Dis 8:208–211CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Crance JM, Scaramozzino N, Jouan A, Garin D (2003) Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 58(1):73–79CrossRefPubMedGoogle Scholar
  6. 6.
    Xu M, Lee EM, Wen Z, Cheng Y, Huang W-K, Qian X et al (2016) Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat Med 22(10):1101–1107CrossRefPubMedGoogle Scholar
  7. 7.
    Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N et al (2015) Biology of Zika virus infection in human skin cells. J Virol 89(17):8880–8896CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sharma A, Lal SK (2017) Zika virus: transmission, detection, control, and prevention. Front Microbiol 8:e0005055Google Scholar
  9. 9.
    Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C et al (2016) Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci USA 113(50):14408–14413CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Abbink P, Larocca RA, La Barrera De RA, Bricault CA, Moseley ET, Boyd M et al (2016) Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353(6304):1129–1132CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB (2016) In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. npj Vaccines. doi: 10.1038/npjvaccines.2016.21
  12. 12.
    Kim E, Erdos G, Huang S, Kenniston T, Falo LD, Gambotto A (2016) Preventative vaccines for Zika virus outbreak: preliminary evaluation. EBIOM 13:315–320CrossRefGoogle Scholar
  13. 13.
    Larocca RA, Abbink P, Peron JPS, de A Zanotto PM, Iampietro MJ, Badamchi-Zadeh A et al (2016) Vaccine protection against Zika virus from Brazil. Nature 536(7617):474–8Google Scholar
  14. 14.
    Pierson TC, Graham BS (2016) Zika virus: immunity and vaccine development. Cell 167(3):625–631CrossRefPubMedGoogle Scholar
  15. 15.
    Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R et al (2015) Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373(13):1195–1206CrossRefPubMedGoogle Scholar
  16. 16.
    Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR et al (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543(7644):248–251CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2017

Authors and Affiliations

  • Marta Díaz-Menéndez
    • 1
    Email author
  • Clara Crespillo-Andújar
    • 1
  1. 1.Tropical Medicine DepartmentHospital Universitario La Paz-Carlos IIIMadridSpain

Personalised recommendations